Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Current Deferred Revenue: 2013-2017

Historic Current Deferred Revenue for Coherus Oncology (CHRS) over the last 2 years, with Mar 2017 value amounting to $669,000.

  • Coherus Oncology's Current Deferred Revenue fell 98.65% to $669,000 in Q1 2017 from the same period last year, while for Mar 2017 it was $669,000, marking a year-over-year decrease of 98.65%. This contributed to the annual value of $892,000 for FY2016, which is 98.20% down from last year.
  • Coherus Oncology's Current Deferred Revenue amounted to $669,000 in Q1 2017, which was down 25.00% from $892,000 recorded in Q4 2016.
  • In the past 5 years, Coherus Oncology's Current Deferred Revenue ranged from a high of $61.3 million in Q2 2016 and a low of $669,000 during Q1 2017.
  • Over the past 3 years, Coherus Oncology's median Current Deferred Revenue value was $28.8 million (recorded in 2015), while the average stood at $27.3 million.
  • Per our database at Business Quant, Coherus Oncology's Current Deferred Revenue surged by 117.69% in 2016 and then tumbled by 98.65% in 2017.
  • Coherus Oncology's Current Deferred Revenue (Quarterly) stood at $14.3 million in 2013, then soared by 59.63% to $22.8 million in 2014, then surged by 117.64% to $49.6 million in 2015, then plummeted by 98.20% to $892,000 in 2016, then crashed by 98.65% to $669,000 in 2017.
  • Its Current Deferred Revenue was $669,000 in Q1 2017, compared to $892,000 in Q4 2016 and $1.4 million in Q3 2016.